Abstract
Synaptic communication requires constant adjustments of pre- and postsynaptic efficacies. In addition to synaptic long term plasticity, the presynaptic machinery underlies homeostatic regulations which prevent out of range transmitter release. In this minireview we will discuss the relevance of selected presynaptic mechanisms to epilepsy including voltage- and ligand-gated ion channels as well as cannabinoid and adenosine receptor signaling.
Introduction
Many studies highlighted the importance of homeostasis in neuronal signaling either within neurons, then called “intrinsic plasticity” or between neurons, referred to as “synaptic scaling” (Davis and Bezprozvanny, 2001; Eichler and Meier, 2008; Turrigiano, 2011). Classic synaptic plasticity in its non-homeostatic “Hebbian” form and pathological disturbances need counterbalancing homeostatic scaling mechanisms (Abbott and Nelson, 2000). The latter was mainly regarded from the postsynaptic perspective (Thiagarajan et al., 2005; Groth et al., 2011). However, in addition to presynaptic expression of synaptic long term plasticity (Nicoll and Schmitz, 2005), slow homeostatic regulations occur in the presynapse, e.g., in form of chronic receptor or ion channel modulations.
Presynaptic ion channel and glycine receptor plasticity
Because transmitter release is controlled by action potential-(AP)-triggered calcium influx in the synaptic terminal, regulation of ion channels which shape the axonal AP and terminal depolarization is an effective mechanism of presynaptic plasticity. With this definition, the AP initiation zone (AIZ) could be viewed as part of the presynaptic equipment. A striking form of homeostatic plasticity has been documented for the AIZ: this entire subcellular structure including voltage-gated Na+ (Nav) and K+ (Kv) channels can be shifted along the axon (Figure 1), thereby counteracting hyperexcitation by increasing thresholds for AP generation (Grubb and Burrone, 2010). Such axonal remodeling may be facilitated via ion channel trafficking regulated by alternative splicing, as shown for “shaw-related” Kv3 channels (Gu et al., 2012). Other important constituents of presynaptic control are “shaker-related” KV1 channels (Wang et al., 1994). Their role is well demonstrated for the large glutamatergic mossy fiber boutons of dentate granule cells, which impinge on hippocampal CA3 pyramidal cells (Geiger and Jonas, 2000; Bischofberger et al., 2006). Here, Kv channels could gain further importance during temporal lobe epilepsy (TLE), when seizures invade the hippocampus and feedforward inhibition of CA3 pyramidal cells via interneurons is compromised (Lawrence and McBain, 2003). Indeed, seizures trigger a transcriptional upregulation of Kv1.1 channels in granule cells, thereby delaying their AP responses considerably, as recently shown in a TLE mouse model (Kirchheim et al., 2013). Consistent with the view that KV1.1 is a promising antiepileptic target, KV1.1 knockout mice develop epilepsy (Wenzel et al., 2007) and lentiviral overexpression of KV1.1 ameliorates seizures in an animal model of neocortical epilepsy (Wykes et al., 2012). The interaction of activity-dependent downscaling and potentiation of presynaptic excitability may involve the adenylyl cyclase pathway (Nicoll and Schmitz, 2005) but it is still unclear how exactly these seemingly opposed mechanisms interact in the same presynaptic compartment.
Figure 1
Epilepsy often comes with cognitive dysfunction and neuropsychiatric comorbidities (García-Morales et al., 2008). We discovered a molecule which in this regard may have an important impact: an RNA variant of the neurotransmitter receptor for glycine (GlyR). The GlyRs are subject to increased RNA editing in resected hippocampi of TLE patients (Eichler et al., 2008) which profoundly influences biophysical receptor properties. The reason is an amino acid substitution in the ligand binding domain leading to gain-of-function receptors with increased neurotransmitter affinity (Meier et al., 2005; Eichler et al., 2008; Legendre et al., 2009) and spontaneous channel activity (Kletke et al., 2013; Winkelmann et al., 2014). In addition, RNA splicing governs presynaptic GlyR expression (Winkelmann et al., 2014), and in hippocampal neurons, the lack of the GlyR β subunit (Weltzien et al., 2012) which governs postsynaptic receptor clustering (Meyer et al., 1995; Meier et al., 2000, 2001; Eichler et al., 2009; Förstera et al., 2010; Kowalczyk et al., 2013), certainly facilitates GlyR expression and function at presynapses (Figure 1). Presynaptic GlyRs are tightly packed (~200 receptor channels in a cluster with ~100 nm radius; Notelaers et al., 2012, 2014a,b), which implies that a single presynaptic cluster from the spontaneously active GlyR RNA variant will have a considerable functional impact on synaptic neurotransmitter release, even if the contribution of the glycinergic system to this brain region appears limited (Zeilhofer et al., 2005). Consistent with the excitatory nature of presynaptic chloride channels and the well documented presynaptic GlyR expression in the hippocampus (Kubota et al., 2010; Ruiz et al., 2010; Waseem and Fedorovich, 2010; Winkelmann et al., 2014), we found that the spontaneously active GlyR RNA variant actually increased presynaptic excitability and the functional impact of glutamatergic neurons or parvalbumin-positive interneurons in vivo and, depending on the type of neuron, triggered cognitive dysfunction or anxiety in our mouse model of epilepsy (Winkelmann et al., 2014). In agreement with the proposed critical role of presynaptic GlyRs in the regulation of neural network excitability, application of a low, non-receptor-saturating, glycine concentration (10 µM) to corticohippocampal slice preparations was sufficient to enhance epileptiform activity induced by block of KV1 channels (Chen et al., 2014).
Retrograde autocrine and paracrine signaling
Although the idea of cannabis as a potential antiepileptic drug is ancient, it remained elusive how it could work reliably (Adams and Martin, 1996; Miller, 2013). Recent discoveries on endogenous cannabinoid receptors (CB), of which particularly CB1 is widely expressed in presynaptic terminals of excitatory and inhibitory neurons (Figure 1), could lead to a better understanding of CB mechanisms in epilepsy (Alger, 2004; Katona and Freund, 2008; Hill et al., 2012). In GABAergic neurons, activation of CB1, e.g., via neuronal activity-dependent retrograde post-to-presynapse release of CBs anandamide or 2-AG has been shown to decrease synaptic GABA release, a mechanism termed depolarization-induced suppression of inhibition (DSI; Ohno-Shosaku et al., 2001; Wilson et al., 2001). Consistently, elevated CB1 presence observed in epilepsy models and TLE patients (Goffin et al., 2011; Karlócai et al., 2011; Bojnik et al., 2012) has been interpreted as proconvulsive (Chen et al., 2003, 2007). On the other hand, CB1 is also expressed on glutamatergic terminals, where its activation reduces glutamate release (Domenici et al., 2006; Kawamura et al., 2006). Furthermore, CB1 activation increases inward rectifier K+ (Kir) currents (Mackie et al., 1995; Chemin et al., 2001) mediated via postsynaptic channels which are also upregulated in TLE (Young et al., 2009; Stegen et al., 2012). In summary, while elevation of CB1 at GABAergic synapses and reduction at glutamatergic synapses likely constitute endogenous adaptations to epilepsy, exogenous CB1 overexpression and activation in principal neurons, possibly via receptors physiologically rarely activated, could effectively protect against seizures (Blair et al., 2006; Guggenhuber et al., 2010; Hofmann and Frazier, 2013).
Adenosine triphosphate (ATP) is released from astrocytes and can enhance neuronal excitability through its direct action onto purinergic receptors. However, ATP can also exert indirect effects upon its enzymatic conversion to adenosine and signaling through adenosine A1 receptors, which reduces synaptic glutamate release (Nicoll and Schmitz, 2005; Boison, 2013; Dias et al., 2013). Therefore, adenosine signaling is another mechanism of presynaptic homeostasis with recognized relevance to epilepsy; while too much adenosine clearance via gliosis-enhanced adenosine kinase activity is a proconvulsive factor, adenosine augmentation in the epileptic focus represents a powerful anticonvulsive principle (Boison, 2012).
Perspective
In agreement with the proposed critical role of presynaptic compartments in the regulation of neural network homeostasis, diverse pharmacological agents with a presynaptic mode of action were reported to be effective in the treatment of epilepsy. In particular drugs which provide rapid adaptation against excessive excitation, e.g., via use-dependent inhibition of Nav or Cav channels (phenytoin, carbamazepine, lamotrigine, topiramate, and levetiracetam), likely act primarily in axons (Stefani et al., 1996; Wu et al., 1998; Catterall, 1999; Vogl et al., 2012). Interestingly, these drugs also have effects on psychiatric symptoms (Barbosa et al., 2003; Lexi-Comp, 2009; Andrus and Gilbert, 2010) indicating common underlying mechanisms of cognitive dysfunction and psychiatric symptoms of epilepsy. With more research on neuron type-specific roles in behavior (Lovett-Barron et al., 2014; Winkelmann et al., 2014), new antiepileptic strategies could ground on these insights and specifically target presynaptic molecules in the affected cell types.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbbottL. F.NelsonS. B. (2000). Synaptic plasticity: taming the beast. Nat. Neurosci.3(Suppl), 1178–1183. 10.1038/81453
2
AdamsI. B.MartinB. R. (1996). Cannabis: pharmacology and toxicology in animals and humans. Addiction91, 1585–1614. 10.1046/j.1360-0443.1996.911115852.x
3
AlgerB. E. (2004). Endocannabinoids and their implications for epilepsy. Epilepsy Curr.4, 169–173. 10.1111/j.1535-7597.2004.04501.x
4
AndrusM. R.GilbertE. (2010). Treatment of civilian and combat-related posttraumatic stress disorder with topiramate. Ann. Pharmacother.44, 1810–1816. 10.1345/aph.1P163
5
BarbosaL.BerkM.VorsterM. (2003). A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J. Clin. Psychiatry64, 403–407. 10.4088/jcp.v64n0407
6
BischofbergerJ.EngelD.FrotscherM.JonasP. (2006). Timing and efficacy of transmitter release at mossy fiber synapses in the hippocampal network. Pflugers Arch.453, 361–372. 10.1007/s00424-006-0093-2
7
BlairR. E.DeshpandeL. S.SombatiS.FalenskiK. W.MartinB. R.DeLorenzoR. J. (2006). Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J. Pharmacol. Exp. Ther.317, 1072–1078. 10.1124/jpet.105.100354
8
BoisonD. (2012). Adenosine dysfunction in epilepsy. Glia60, 1234–1243. 10.1002/glia.22285
9
BoisonD. (2013). Adenosine kinase: exploitation for therapeutic gain. Pharmacol. Rev.65, 906–943. 10.1124/pr.112.006361
10
BojnikE.TuruncE.ArmaganG.KanitL.BenyheS.YalcinA.et al. (2012). Changes in the cannabinoid (CB1) receptor expression level and G-protein activation in kainic acid induced seizures. Epilepsy Res.99, 64–68. 10.1016/j.eplepsyres.2011.10.020
11
CatterallW. A. (1999). Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv. Neurol.79, 441–456.
12
CheminJ.MonteilA.Perez-ReyesE.NargeotJ.LoryP. (2001). Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J.20, 7033–7040. 10.1093/emboj/20.24.7033
13
ChenK.NeuA.HowardA. L.FoldyC.EchegoyenJ.HilgenbergL.et al. (2007). Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J. Neurosci.27, 46–58. 10.1523/jneurosci.3966-06.2007
14
ChenR.OkabeA.SunH.SharopovS.Hanganu-OpatzI. L.KolbaevS. N.et al. (2014). Activation of glycine receptors modulates spontaneous epileptiform activity in the immature rat hippocampus. J. Physiol.592(Pt. 10), 2153–2168. 10.1113/jphysiol.2014.271700
15
ChenK.RatzliffA.HilgenbergL.GulyasA.FreundT. F.SmithM.et al. (2003). Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron39, 599–611. 10.1016/s0896-6273(03)00499-9
16
DavisG. W.BezprozvannyI. (2001). Maintaining the stability of neural function: a homeostatic hypothesis. Annu. Rev. Physiol.63, 847–869. 10.1146/annurev.physiol.63.1.847
17
DiasR. B.RomboD. M.RibeiroJ. A.HenleyJ. M.SebastiaoA. M. (2013). Adenosine: setting the stage for plasticity. Trends Neurosci.36, 248–257. 10.1016/j.tins.2012.12.003
18
DomeniciM. R.AzadS. C.MarsicanoG.SchierlohA.WotjakC. T.DodtH. U.et al. (2006). Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J. Neurosci.26, 5794–5799. 10.1523/jneurosci.0372-06.2006
19
EichlerS. A.FörsteraB.SmolinskyB.JuttnerR.LehmannT. N.FahlingM.et al. (2009). Splice-specific roles of glycine receptor α3 in the hippocampus. Eur. J. Neurosci.30, 1077–1091. 10.1111/j.1460-9568.2009.06903.x
20
EichlerS. A.KirischukS.JüttnerR.SchäfermeierP. K.LegendreP.LehmannT. N.et al. (2008). Glycinergic tonic inhibition of hippocampal neurons with depolarising GABAergic transmission elicits histopathological signs of temporal lobe epilepsy. J. Cell. Mol. Med.12, 2848–2866. 10.1111/j.1582-4934.2008.00357.x
21
EichlerS. A.MeierJ. C. (2008). E-I balance and human diseases - from molecules to networking. Front. Mol. Neurosci.1:2. 10.3389/neuro.02.002.2008
22
FörsteraB.BelaidiA. A.JüttnerR.BernertC.TsokosM.LehmannT. N.et al. (2010). Irregular RNA splicing curtails postsynaptic gephyrin in the cornu ammonis of patients with epilepsy. Brain133, 3778–3794. 10.1093/brain/awq298
23
García-MoralesI.de la PenaM. P.KannerA. M. (2008). Psychiatric comorbidities in epilepsy: identification and treatment. Neurologist14, S15–S25. 10.1097/01.nrl.0000340788.07672.51
24
GeigerJ. R.JonasP. (2000). Dynamic control of presynaptic Ca(2+) inflow by fast-inactivating K(+) channels in hippocampal mossy fiber boutons. Neuron28, 927–939. 10.1016/s0896-6273(00)00164-1
25
GoffinK.VanP. W.VanL. K. (2011). In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain134, 1033–1040. 10.1093/brain/awq385
26
GrothR. D.LindskogM.ThiagarajanT. C.LiL.TsienR. W. (2011). Beta Ca2+/CaM-dependent kinase type II triggers upregulation of GluA1 to coordinate adaptation to synaptic inactivity in hippocampal neurons. Proc. Natl. Acad. Sci. U S A108, 828–833. 10.1073/pnas.1018022108
27
GrubbM. S.BurroneJ. (2010). Activity-dependent relocation of the axon initial segment fine-tunes neuronal excitability. Nature465, 1070–1074. 10.1038/nature09160
28
GuY.BarryJ.McDougelR.TermanD.GuC. (2012). Alternative splicing regulates kv3.1 polarized targeting to adjust maximal spiking frequency. J. Biol. Chem.287, 1755–1769. 10.1074/jbc.m111.299305
29
GuggenhuberS.MonoryK.LutzB.KlugmannM. (2010). AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity. PLoS One5:e15707. 10.1371/journal.pone.0015707
30
HillA. J.WilliamsC. M.WhalleyB. J.StephensG. J. (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Ther.133, 79–97. 10.1016/j.pharmthera.2011.09.002
31
HofmannM. E.FrazierC. J. (2013). Marijuana, endocannabinoids and epilepsy: potential and challenges for improved therapeutic intervention. Exp. Neurol.244, 43–50. 10.1016/j.expneurol.2011.11.047
32
KarlócaiM. R.TothK.WatanabeM.LedentC.JuhaszG.FreundT. F.et al. (2011). Redistribution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-induced epilepsy. PLoS One6:e27196. 10.1371/journal.pone.0027196
33
KatonaI.FreundT. F. (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med.14, 923–930. 10.1038/nm.f.1869
34
KawamuraY.FukayaM.MaejimaT.YoshidaT.MiuraE.WatanabeM.et al. (2006). The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J. Neurosci.26, 2991–3001. 10.1523/jneurosci.4872-05.2006
35
KirchheimF.TinnesS.HaasC. A.StegenM.WolfartJ. (2013). Regulation of action potential delays via voltage-gated potassium Kv1.1 channels in dentate granule cells during hippocampal epilepsy. Front. Cell. Neurosci.7:248. 10.3389/fncel.2013.00248
36
KletkeO.SergeevaO. A.LorenzP.OberlandS.MeierJ. C.HattH.et al. (2013). New insights in endogenous modulation of ligand-gated ion channels: Histamine is an inverse agonist at strychnine sensitive glycine receptors. Eur. J. Pharmacol.710, 59–66. 10.1016/j.ejphar.2013.04.002
37
KowalczykS.WinkelmannA.SmolinskyB.FörsteraB.NeundorfI.SchwarzG.et al. (2013). Direct binding of GABA(A) receptor β2 and β3 subunits to gephyrin. Eur. J. Neurosci.37, 544–554. 10.1111/ejn.12078
38
KubotaH.AlleH.BetzH.GeigerJ. R. (2010). Presynaptic glycine receptors on hippocampal mossy fibers. Biochem. Biophys. Res. Commun.393, 587–591. 10.1016/j.bbrc.2010.02.019
39
LawrenceJ. J.McBainC. J. (2003). Interneuron diversity series: containing the detonation—feedforward inhibition in the CA3 hippocampus. Trends Neurosci.26, 631–640. 10.1016/j.tins.2003.09.007
40
LegendreP.FörsteraB.JüttnerR.MeierJ. C. (2009). Glycine receptors caught between genome and proteome—functional implications of RNA editing and splicing. Front. Mol. Neurosci.2:23. 10.3389/neuro.02.023.2009
41
Lexi-Comp. (2009). “Carbamazepine,” in The Merck Manual, ed PorterR. S. (Whitehouse Station, N.J., U.S.A: Merck Sharp and Dohme Corp., a subsidiary of Merck and Co., Inc.).
42
Lovett-BarronM.KaifoshP.KheirbekM. A.DanielsonN.ZarembaJ. D.ReardonT. R.et al. (2014). Dendritic inhibition in the hippocampus supports fear learning. Science343, 857–863. 10.1126/science.1247485
43
MackieK.LaiY.WestenbroekR.MitchellR. (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci.15, 6552–6561.
44
MeierJ. C.HennebergerC.MelnickI.RaccaC.HarveyR. J.HeinemannU.et al. (2005). RNA editing produces glycine receptor α3P185L resulting in high agonist potency. Nat. Neurosci.8, 736–744. 10.1038/nn1467
45
MeierJ.Meunier-DurmortC.ForestC.TrillerA.VannierC. (2000). Formation of glycine receptor clusters and their accumulation at synapses. J. Cell Sci.113, 2783–2795.
46
MeierJ.VannierC.SergeA.TrillerA.ChoquetD. (2001). Fast and reversible trapping of surface glycine receptors by gephyrin. Nat. Neurosci.4, 253–260. 10.1038/85099
47
MeyerG.KirschJ.BetzH.LangoschD. (1995). Identification of a gephyrin binding motif on the glycine receptor beta subunit. Neuron15, 563–572. 10.1016/0896-6273(95)90145-0
48
MillerJ. W. (2013). Slim evidence for cannabinoids for epilepsy. Epilepsy Curr.13, 81–82. 10.5698/1535-7597-13.2.81
49
NicollR. A.SchmitzD. (2005). Synaptic plasticity at hippocampal mossy fibre synapses. Nat. Rev. Neurosci.6, 863–876. 10.1038/nrn1786
50
NotelaersK.SmisdomN.RochaS.JanssenD.MeierJ. C.RigoJ. M.et al. (2012). Ensemble and single particle fluorimetric techniques in concerted action to study the diffusion and aggregation of the glycine receptor alpha3 isoforms in the cell plasma membrane. Biochim. Biophys. Acta1818, 3131–3140. 10.1016/j.bbamem.2012.08.010
51
NotelaersK.RochaS.PaesenR.SmisdomN.DeC. B.MeierJ. C.et al. (2014a). Analysis of alpha3 GlyR single particle tracking in the cell membrane. Biochim. Biophys. Acta1843, 544–553. 10.1016/j.bbamcr.2013.11.019
52
NotelaersK.RochaS.PaesenR.SwinnenN.VangindertaelJ.MeierJ. C.et al. (2014b). Membrane distribution of the glycine receptor alpha3 studied by optical super-resolution microscopy. Histochem. Cell Biol. [Epub ahead of print]. 10.1007/s00418-014-1197-y
53
Ohno-ShosakuT.MaejimaT.KanoM. (2001). Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron29, 729–738. 10.1016/s0896-6273(01)00247-1
54
RuizA.CampanacE.ScottR. S.RusakovD. A.KullmannD. M. (2010). Presynaptic GABAA receptors enhance transmission and LTP induction at hippocampal mossy fiber synapses. Nat. Neurosci.13, 431–438. 10.1038/nn.2512
55
StefaniA.SpadoniF.SiniscalchiA.BernardiG. (1996). Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur. J. Pharmacol.307, 113–116. 10.1016/0014-2999(96)00265-8
56
StegenM.KirchheimF.HanuschkinA.StaszewskiO.VehR. W.WolfartJ. (2012). Adaptive intrinsic plasticity in human dentate gyrus granule cells during temporal lobe epilepsy. Cereb. Cortex22, 2087–2101. 10.1093/cercor/bhr294
57
ThiagarajanT. C.LindskogM.TsienR. W. (2005). Adaptation to synaptic inactivity in hippocampal neurons. Neuron47, 725–737. 10.1016/j.neuron.2005.06.037
58
TurrigianoG. (2011). Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement. Annu. Rev. Neurosci.34, 89–103. 10.1146/annurev-neuro-060909-153238
59
VoglC.MochidaS.WolffC.WhalleyB. J.StephensG. J. (2012). The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway. Mol. Pharmacol.82, 199–208. 10.1124/mol.111.076687
60
WangH.KunkelD. D.SchwartzkroinP. A.TempelB. L. (1994). Localization of Kv1.1 and Kv1.2, two K channel proteins, to synaptic terminals, somata and dendrites in the mouse brain. J. Neurosci.14, 4588–4599.
61
WaseemT. V.FedorovichS. V. (2010). Presynaptic glycine receptors influence plasma membrane potential and glutamate release. Neurochem. Res.35, 1188–1195. 10.1007/s11064-010-0174-7
62
WeltzienF.PullerC.O’SullivanG. A.PaarmannI.BetzH. (2012). Distribution of the glycine receptor beta-subunit in the mouse CNS as revealed by a novel monoclonal antibody. J. Comp. Neurol.520, 3962–3981. 10.1002/cne.23139
63
WenzelH. J.VacherH.ClarkE.TrimmerJ. S.LeeA. L.SapolskyR. M.et al. (2007). Structural consequences of Kcna1 gene deletion and transfer in the mouse hippocampus. Epilepsia48, 2023–2046. 10.1111/j.1528-1167.2007.01189.x
64
WilsonR. I.KunosG.NicollR. A. (2001). Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron31, 453–462. 10.1016/s0896-6273(01)00372-5
65
WinkelmannA.MaggioN.EllerJ.CaliskanG.SemtnerM.HäusslerU.et al. (2014). Changes in neural network homeostasis trigger neuropsychiatric symptoms. J. Clin. Invest.124, 696–711. 10.1172/jci71472
66
WuS. P.TsaiJ. J.GeanP. W. (1998). Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices. Br. J. Pharmacol.125, 826–832. 10.1038/sj.bjp.0702096
67
WykesR. C.HeeromaJ. H.MantoanL.ZhengK.MacDonaldD. C.DeisserothK.et al. (2012). Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci. Transl. Med.4:161ra152. 10.1126/scitranslmed.3004190
68
YoungC. C.StegenM.BernardR.MullerM.BischofbergerJ.VehR. W.et al. (2009). Upregulation of inward rectifier K+ (Kir2) channels in dentate gyrus granule cells in temporal lobe epilepsy. J. Physiol.587, 4213–4233. 10.1113/jphysiol.2009.170746
69
ZeilhoferH. U.StudlerB.ArabadziszD.SchweizerC.AhmadiS.LayhB.et al. (2005). Glycinergic neurons expressing enhanced green fluorescent protein in bacterial artificial chromosome transgenic mice. J. Comp. Neurol.482, 123–141. 10.1002/cne.20349
Summary
Keywords
epilepsy, axon, RNA editing, potassium channels, glycine receptor, homeostatic regulation, neuropsychiatric disorders, hippocampus
Citation
Meier JC, Semtner M, Winkelmann A and Wolfart J (2014) Presynaptic mechanisms of neuronal plasticity and their role in epilepsy. Front. Cell. Neurosci. 8:164. doi: 10.3389/fncel.2014.00164
Received
22 April 2014
Accepted
29 May 2014
Published
17 June 2014
Volume
8 - 2014
Edited by
Jaichandar Subramanian, Massachusetts Institute of Technology, USA
Reviewed by
Detlev Boison, Legacy Research Institute, USA; Rory McQuiston, Virginia Commonwealth University, USA
Copyright
© 2014 Meier, Semtner, Winkelmann and Wolfart.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jochen C. Meier, RNA Editing and Hyperexcitability Disorders, Max Delbrück Centre for Molecular Medicine, Neurosciences, Building C31.2, Robert-Rössle-Straße 10, 13125 Berlin, Germany e-mail: jochen.meier@mdc-berlin.de
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.